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Purpose: The purpose of the study is to identify risk factors for noninvasive ventilation (NIV) failure in cancer
patients with acute respiratory failure (ARF).
Materials and methods: A retrospective cohort study of adult patients admitted to intensive care unit (ICU), who
received NIV for treatment of ARF, was conducted. We conducted a chart review to estimate the NIV failure rate
and used logistic regression to identify risk factors.
Results:Of 2258 patients admitted to the ICU during the study period, 114 (5%) receivedNIV for ARF. Noninvasive
ventilation was successful in 67 patients (59%) and failed for 47 (41%), of whom 36were intubated and 11 were
sedated for palliation. Factors associated with NIV failure were infection as the primary cause of ARF (odds ratio
[OR], 4.90; 95% conﬁdence interval [CI], 1.78-13.45; P= .002), male sex (OR, 2.58; 95% CI, 1.20-5.56; P= .015),
and Simpliﬁed Acute Physiology Score 3 (OR, 1.04; 95% CI, 1.01-1.07; P= .006). Overall ICU mortality was 40%,
and hospital mortality was 56%. Noninvasive ventilation failure was the only independent predictor of ICU
mortality (OR, 16.6; 95% CI, 6.5-41.5; P b .001).
Conclusions:Noninvasive ventilation can avert ARF for most ICU cancer patients with ARF. For patients with
pulmonary infections and high severity scores, NIV should be used with caution. Identifying risk factors
for NIV failure using a comprehensive diagnostic approach and monitoring of NIV are paramount to
improve outcomes.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
The number of patients with cancer admitted to intensive care unit
(ICU) has increased over time as a result of increased survival rates re-
ported over the last decade [1-5]. Greater survival rates for critically ill
cancer patients have been associated to advances in anticancer treat-
ments and critical care, early diagnosis and treatment of organ dysfunc-
tion, and improved screening techniques of patients referred for ICU
admission [2,5-9]. However, these survival gains have come at the cost
of increased toxicity and complications. Chemotherapy and radiation
toxicity, metastatic lung disease, heart failure, immunosuppression, re-
spiratory infection, and sepsis are some of themain causes of ICU admis-
sion of patients with cancer [10,11]. Among these complications, acute
respiratory failure (ARF) occurs in up to 30% of cancer patients and isia HC-InCor, Av Dr. Enéas de
lo, SP, CEP 05403000, Brazil.
rreira),
ni@gmail.com (F.M. Rego),the leading cause for ICU admission in this population [2,12,13]. Acute
respiratory failure in cancer patients still carries a high mortality rate
of 50% overall, with even higher rates in patients requiring mechanical
ventilation [2,13-15].
The use of noninvasive ventilation (NIV), in the form of noninvasive
positive pressure ventilation and noninvasive continuous positive
airway pressure, has also increased substantially for acutely ill patients,
especially over the last 2 decades [16-18].
Noninvasive ventilation has been shown to reduce intubation and
mortality rates for speciﬁc populations and is increasingly used to
treat ARF of several causes [19,20]. Cancer patients with ARFmight par-
ticularly beneﬁt from the use of NIV, due to their increased risk for 3
major indications of NIV: chronic obstructive pulmonary disease
(COPD), immunosuppression, and cardiogenic pulmonary edema relat-
ed to cardiac toxicity of anticancer agents and hyperhydration during
chemotherapy. However, despite all potential beneﬁts of NIV in treating
ARF, NIV failure has been associated with increased mortality, and fail-
ure rates and risk factors for NIV failure in cancer patients have received
limited attention.
The primary objective of this study was to identify risk factors for
NIV failure in cancer patients with ARF. Secondary objective was to esti-
mate ICU and hospital mortality among ICU patients who developed
Table 1
Baseline characteristics of patients (n = 114)
Age (y) 64 ± 14a
Sex (M/F) 50/64
Days in hospital before admission 4 (1-9)b
SAPS 3 score 70 ± 16a
ECOG scale (2 wk before admission)
0-2 85 (75%)
3-4 29 (25%)
Type of admission
Medical 97 (85%)
Elective surgery 14 (12%)
Emergency surgery 3 (3%)
Main reason for admission
Respiratory failure 68 (60%)
Sepsis 19 (17%)
PO monitoring 17 (15%)
Other 10 (9%)
Cause of respiratory failure
Infection 51 (45%)
Cardiogenic pulmonary edema 31 (27%)
Sepsis 5 (4%)
Other 27 (24%)
PO indicates postoperative.
a Mean ± SD.
b Median (25%-75% percentiles); other values are counts (percentages).
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cohort study of patients admitted to the ICU of a large cancer hospital
over a 1-year period.
2. Materials and methods
2.1. Patients and data collection
The institution's ethics committee approved the study and waived
the requirement for informed consent due to its observational,
retrospective nature.
All electronic records of consecutive adult patients admitted to a 31-
bed ICU in a tertiary cancer hospital in São Paulo, Brazil, between
January and December of 2010, were reviewed. We included patients
who received NIV as the ﬁrst line of treatment for ARF during the ICU
stay. Decision to apply NIV or invasive mechanical ventilation (MV)
was based on clinical judgment of the ICU physician, guided by current
guidelines [19]. In our ICU, NIV for ARF is delivered by dedicated NIV
mechanical ventilators (Vision; Philips Respironics, Murrysville, PA),
using bilevel support and orofacial or total face masks. Patients who re-
ceived NIV exclusively for postextubation ARF and patients admitted to
the ICU under exclusive palliative care were excluded. Outcomes of in-
terestwere NIV failure, ICUmortality, hospitalmortality, and ICU length
of stay (LOS).
We used a structured collection form to register demographics,
primary cancer site, presence of metastasis, previous performance
status using the Eastern Cooperative Oncology Group (ECOG) scale,
reason for ICU admission, primary cause of ARF, severity of the
acute disease using the Simpliﬁed Acute Physiology Score (SAPS) 3
[21] at ICU admission, duration of NIV support, use of invasive venti-
latory support, ICU discharge status, and decision to withdraw or
withhold treatment.
We classiﬁed the cause of ICU admission and primary cause of
ARF into prespeciﬁed categories by careful review of the medical
chart. Pulmonary infection was considered to be the primary cause
of ARF if pneumonia or acute tracheobronchitis were pointed by
the ICU team as the cause of ARF and need for NIV. A positive culture
was not required.
Noninvasive ventilation failurewas deﬁned as the need for intuba-
tion and invasive MV or sedation for comfort when medical staff, pa-
tients, and families agreed that intubation was not to be performed
and further classiﬁed as early, if NIV was used for less than 24
hours before intubation, or late, if otherwise. Decision to proceed to
intubation was at the ICU team discretion but guided by current
guidelines. Independent researchers ﬁlled a collecting sheet, and
data were double checked.
2.2. Statistical analysis
The primary outcomemeasure was NIV failure. Categorical variables
are reported as percentages, and continuous variables, asmeans and SD,
when normally distributed, or medians and 25% to 75% percentiles,
when otherwise.
Comparison of continuous variables between patients who failed
NIV or did not was performed using the t test for normally distributed
variables or the Mann-Whitney U test. Comparison between groups
for categorical variableswas performedusing theχ2 test. Categorical di-
chotomous variables were coded as 0 (absence) or 1 (presence). Cate-
gorical factors with more than 2 levels were coded using a dummy
variable system, and the reference categorywas the level less associated
with the primary outcome.
For the univariate analysis of several risk factors and the outcome,
we used a univariate logistic regressionmodel. To estimate the complex
effects of multiple variables on NIV failure, we performed amultivariate
analysis using a conditional logistic regression model with the forward
stepwise selection method. Variables were included in the model ifthey were associated with the outcome on the univariate analysis
with a P value equal or less than .10. Statistical analysis was performed
with SPSS version 13.0 (SPSS, Inc, Chicago, IL).
3. Results
Of the 2258 patients admitted to the ICU in 2010, 114 (5%) received
NIV for ARF. Patients' characteristics at admission are shown on Table 1.
The median duration of noninvasive support was 2 (1-3) days, and
the median ICU LOS was 6 (3-11) days. Noninvasive ventilation was
successful in reversing respiratory failure in 67 patients (59%) and failed
in 47 patients (41%) (Table 2). Twenty patients had early NIV failure,
whereas 27 had late failure, but no signiﬁcant differences between
these 2 groups were observed. Fourteen patients had hematological
cancer, and no differences in outcomes in comparison with solid organ
cancer patients were observed. Median ICU LOS was 9 (4-15) days for
patients who had NIV success and 7 (6-10) days for patients with NIV
failure (P=.047). For 11 of the 47patients forwhomNIV failed,medical
staff, patients, and families agreed that intubation was not to be per-
formed, and palliative care with sedation was instituted. Among pa-
tients who failed NIV, those who were not intubated and received
exclusive palliative care had longer duration of NIV support (4 vs 2
days; P = .0055) and shorter ICU stay (4 vs 10; P = .006) compared
to thosewhowere intubated (Supplementary Table 2). Compared topa-
tients who improved with the use of NIV, patients who failed NIV were
more likely to be male, had higher SAPS 3 scores, and were more likely
to have infection as the primary cause of respiratory failure (Table 3).
These factors remained signiﬁcantly associated with NIV failure after
adjustment for covariates with the multivariate logistic regression
model (Table 4). As a sensitivity analysis, we repeated the analysis ex-
cluding the 11 patients who failed NIV and were not intubated, and
we found similar results (Supplementary Table 1).
Intensive care unit mortality was 40%, and risk factors associated
with ICU mortality were the primary cause of respiratory failure, SAPS
3 score, male sex, and NIV failure. The multivariate logistic regression
model identiﬁed NIV failure as the only independent predictor of ICU
mortality, with an odds ratio (OR) of 16.6 (95% conﬁdence interval
[CI], 6.5-41.5) (P b .001). Intensive care unit mortality among patients
who failed NIV was 74%, compared to only 15% for those who had NIV
success (P b .001).
For patients who failed NIV and were not intubated because they
were under palliative care, ICU mortality was 100%.
Table 2
Main outcomes (n = 114)
Duration of NIV support (d) 2 (1-3)a
ICU LOS (d) 6 (3-11)a
NIV failure 47 (41%)
Intubation and MV 36
Palliative care 11
ICU mortality 45 (40%)
Hospital mortality 64 (56%)
a Median (25%-75% percentiles); other values are counts (percentages).
Table 4
Factors associated with NIV failure
OR (95% CI) P OR (95% CI) P
Univariate Multivariate
Age, each additional year 1.02 (0.99-1.06) .104
Sex
Male 2.58 (1.20-5.56) .015 2.42 (1.06-5.55) .037
Female
SAPS 3 score,
each additional point
1.04 (1.01-1.07) .006 1.03 (1.001-1.06) .043
Cause of respiratory failure
Infection 4.90 (1.78-13.45) .002 3.55 (1.23-10.28) .019
Cardiogenic REF* REF*
Other 1.56 (0.51-4.81) .44 1.45 (0.45-4.68) .531
Days in hospital
before admission
1.04 (0.999-1.09) .058
P values obtained with logistic regression, univariate and multivariate; *REF: cardiogenic
pulmonary edema was used as the reference category in logistic regression when the
cause of respiratory failure was added to the model. As a result, ORs for infection and
“other” reﬂect the OR of NIV failure in relation to cardiogenic pulmonary edema.
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on the hospital wards, resulting in an overall hospital mortality of 56%
for the original population.
4. Discussion
In our cohort of cancer patients with respiratory failure admitted to
the ICU, we observed that NIV was successful in reversing respiratory
failure in nearly 60% of these unselected cancer patients admitted to
the ICU for any cause. Risk factors for NIV failure were male sex, more
severe acute disease at ICU admission, and respiratory infection as the
cause of ARF. Intensive care unit mortality was 40%, and NIV failure
was strongly associated with ICUmortality. Hospital mortality was 56%.
4.1. Noninvasive ventilation failure
Noninvasive ventilation utilization is increasing in the last decades
[16-18] as an alternative to intubation and MV. For cancer patients,
NIV can be particularly appealing as a less invasive alternative to treat
ARF in patients who have already been submitted to aggressive treat-
ments and has become a useful tool, linked to improved survival in
recent years [2,22].
However, NIV failure rates vary across studies with cancer patients
from 25% up to 70% [2,13,23-26], and there is increasing concern with
NIV failure being associated with worse clinical outcomes [17,18].
In our population, NIV failed to reverse ARF in 47 (41%) of the cases,
and factors associated with failure were being male, higher SAPS 3
scores at admission, and respiratory infection as the primary cause of
ARF. Severity scores at ICU admission and pneumonia have been alreadyTable 3
Comparison between patients with successful or failed NIV
Failure (n = 47) Success (n = 67) P
Age (y), mean ± SD 67 ± 11a 63 ± 15a .101
Sex .014
Male 27 (57%) 23 (34%)
Female 20 (43%) 44 (66%)
SAPS 3 score, mean ± SD 75 ± 16a 66 ± 15a .004
ECOG scale (2 wk before admission) .393
0-2 37 (79%) 48 (72%)
3-4 10 (21%) 19 (28%)
Cause of respiratory failure .002
Infection 30 (64%) 21 (31%)
Cardiogenic 7 (15%) 24 (36%)
Other 10 (21%) 22 (33%)
Type of admission .955
Medical 40 (85%) 57 (85%)
Elective surgery 6 (13%) 8 (12%)
Emergency surgery 1 (1%) 2 (3%)
Days in hospital before admission 4 (1-13)b 3 (1-8)b .364
Duration of NIV support (d) 2 (1-4)b 2 (1-3)b .51
Respiratory rate during NIV 21 ± 7a 21 ± 5a .51
ICU LOS (d) 7 (6-10)b 9 (4-15)b .047
ICU mortality 35 (74%) 10 (15%) b .001
P values for univariate analysis using t or Mann-Whitney U test for continuous variables
and Person χ2 for categorical variables.
a Mean ± SD.
b Median (25%-75% percentiles); other values are counts (percentages).identiﬁed as risk factors for NIV failure in broader populations of critical
patients. Other previously described risk factors for NIV failure areAcute
Respiratory Distress Syndrome (ARDS) and no improvement in blood
gases or respiratory rate 1 to 2 hours after NIV initiation [27-31], al-
though these last 2 factors could be better described as indicators that
NIV is not being effective, rather than risk factors per se.
Only a few previous studies evaluated risk factors for NIV failure in
cancer patients: Azoulay et al [2] evaluated a prospective cohort of
203 patients and observed 57% of NIV failure. Risk factors for NIV failure
were longer NIV duration and ARDS or extensive lung involvement,
which led the authors to hypothesize that the use of NIV delayed intu-
bation and patients received suboptimal management for ARDS. In our
sample, evaluated a decade later, NIV duration was not longer for pa-
tientswho failed,maybe reﬂecting accumulated awareness that delayed
intubation may be harmful. Azevedo et al [13] prospectively studied 85
cancer patientswith ARF treatedwithNIV and reported 53% failure. Risk
factors for NIV failurewere septic shock, ARDS, and high respiratory rate
on the ﬁrst day of NIV. ARDS was not prevalent in our population be-
cause, in our ICU, these patients are typically managed with invasive
MV. We did not observe an effect of respiratory rate on NIV failure,
but due to the retrospective nature of our data, this parameter is not
as reliable. Among the speciﬁc hematologic cancer population, male
sex, severity scores, and higher respiratory rate during NIV have been
identiﬁed as risk factors, and 1 study found that congestive heart failure
and bacteremia were protective against NIV failure [25,32,33]
Our ﬁnding that pulmonary infection is an independent risk factor
for NIV failure in cancer patients has important clinical implications. Al-
though Azevedo et al already identiﬁed septic shock as a risk factor for
NIV failure, separating respiratory infection from the broad category of
septic shock is important because patients with septic shock may pres-
ent with impaired mental status and/or hemodynamic instability,
which are relative contraindications for NIV. The clinician who admits
a cancer patient with septic shock and need for vasopressors or ARDS
to the ICU may be inclined to proceed to intubation and invasive MV
but be more permissive to try NIV with a patient who is hemodynami-
cally stable and has a suspected pulmonary infection. Our results sug-
gest that, for cancer patients admitted to the ICU with ARF caused by
conﬁrmed or suspected infection, NIV should be used with caution,
with closemonitoring, and intubation performed if no signs of improve-
ment are noted in the ﬁrst few hours.
In our study, cardiogenic pulmonary edema was associated with
lower NIV failure rates (23%) than pulmonary infection (59%), which
is in agreement with several previous studies that show that NIV re-
duces complications and mortality for cardiogenic pulmonary edema
but is not as effective for pneumonia [34-36]. Most recent guidelines
recommend the use of NIV for patients with cardiogenic pulmonary
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such recommendation for pneumonia [19,20]. The interesting ﬁnding
here is that, despite these recommendations, NIV was used to treat pul-
monary infection–related ARF in 51 patients in our sample. One possible
explanation is that ARF in cancer patients may bemultifactorial and not
easily attributed to one or other cause at admission. Patients may have
received cardiotoxic chemotherapy and have a positive cumulative
ﬂuid balance, their immune systems are vulnerable, and many are ex-
smokers and could have undiagnosed COPD. Moreover, the positive re-
sults of NIV for exacerbation of COPD, cardiogenic pulmonary edema,
and immunosuppressed patients have been shown to be associated with
an increase in NIV usage in recent years for all causes of ARF [16-18,37]
and may lead clinicians to consider an NIV trial for most cancer patients
with ARF who do not have a contraindication for it because many studies
in cancer patients have shown that NIV was associated with better
outcomes than invasive MV [2,13,22-24,26].
However, recent studies also report that patientswho are initially on
NIV but fail and need invasive ventilation have mortality rates higher
than those who were managed with invasive ventilation from time
zero. This increased mortality may be related to delayed intubation in
patients who fail NIV, which has been reported for many populations
[17,18,38], including cancer patients [2,10,13,22-25]. In our population,
the median duration of NIV was not different for patients who failed or
succeeded NIV, but that does not rule out the possibility that, for any
given patient, NIV delayed intubation.
Our sample includes 11 patients who were admitted to the ICU for
full support, but when NIV failed to avert ARF, a decision was made
not to intubate, but rather offer palliative support. These patients were
not excluded from the study because ourmain outcomewasNIV failure,
not mortality. These patients constitute a subpopulation of cancer pa-
tients with ARF who may be admitted to ICUs for so called “ICU trials,”
in which high-risk patients are offered full ICU support for 48 to 72
hours, allowing for potentially reversible causes of organ failure to re-
spond to treatment. In our ICU, as in other Brazilian ICUs, patients
with do-not-intubate orders may be admitted to the ICU to be submit-
ted to an ICU trial, and NIV is used as part of the initial treatment,
when indicated. Such patients may not be admitted to the ICU in coun-
tries or hospitals with shortage of ICU beds or other admission criteria
policies. To test if this particular subpopulation could have impacted
the results of our study, we conducted a sensitivity analysis excluding
these 11 patients and found similar results (see Supplementary
Table 1). This ﬁnding reinforces the interpretation that risk factors for
NIV failure found in our study appear to be valid for a broad population
of cancer patients requiring noninvasive ventilatory support, including
patients with advanced cancer undergoing ICU trials.
4.2. Mortality
Intensive care unit mortality in our population was 40%, similar to
recent studies showing decreasing mortality in cancer patients
admitted to ICU [1-3]. About a decade ago, the overall survival of onco-
logic patients admitted to the ICU was approximately 50%, but for the
subgroup of patients requiring MV, it was particularly high, ranging
from 90% in the middle of the 1990 to 75% to 80% at the turn of the
century [2,4,22,32,39].
More recently, several studies have reported lowermortality among
cancer patients admitted to the ICU, around 30% [3,12,13,22,39], a de-
crease also noted in the largest observational study performed in cancer
patients admitted to ICUs in Latin America,which reported ICUmortality
of 21% and hospital mortality of 30% [4]. In the subpopulation with ARF,
mortality rates from recent studies range from42% to 69% [2,3,13,23,25].
The decrease in mortality has been attributed to improvements in
cancer treatment and ICU care, early invasive diagnostic evaluation
[7,8,40], and use of NIV [3,12,22].
Risk factors associated with ICUmortality in our study were the pri-
mary cause of respiratory failure, SAPS 3 score,male sex, andNIV failure,but on multivariate analysis, NIV failure was the only independent risk
factor. Of the 69 patients discharged alive from the ICU, 19 (28%) died
in the wards, resulting in 56% of hospital mortality for the entire popu-
lation. This relatively high mortality rate after ICU discharge reﬂects the
severity of disease of our population and may also reﬂect post-ICU
management or the transition to palliative care after ICU discharge.
Of the 47 patients who failed NIV in our sample, 11 were not
intubated and instead received light sedation and end-of-life care,
showing 100% ICU mortality. Exclusive palliative treatment at admis-
sion was an exclusion criterion in our study, but a decision not to intu-
bate could be made as the patient showed no signs of recovery and
family and ICU staff felt that intubationwould be futile. Previous studies
have shown that NIV can be used to avert ARF in palliative patients with
do-not-intubate orders, reduce dyspnea and need for morphine, and
prepare for death as part of end-of-life care [41-43]. In the subpopula-
tion of cancer patients, however, evidence is scarcer. Because exclusive
palliative treatment directive was not explicit for any of our patients at
admission, and became apparent only for the cases that failed NIV, we
cannot estimate the proportion of similar patientswhowere successfully
treated with NIV.
Some limitations of our study should be taken into account. As any
retrospective study, relevant information may not have been registered
into patients' medical records. For our study, the presence of important
comorbidities as COPDmay have been underestimated. Respiratory pa-
rameters may also have been inaccurate or missing by the retrospective
retrieval of data, and to minimize that, we used data from medical,
nurse, and respiratory therapist records. The main cause of respiratory
failure was dependent on the degree of diagnostic efforts applied to
each patient, and inaccuracies cannot be ruled out.
Clinical recognition ofNIV failure anddecision to proceed to intubation
and invasiveMVwere based on ICU team clinical judgment and, given the
observational nature of our study, not controlled or protocolized.
5. Conclusions
In conclusion, our study shows that NIV can avert ARF for most can-
cer patients admitted to the ICU, especiallywhen the cause of ARF is car-
diogenic pulmonary edema. For patients presentingwith ARF caused by
pulmonary infections and high severity scores at ICU admission, NIV
should be used with caution. Our ﬁndings and those of previous studies
suggest that identifying risk factors for NIV failure in cancer patients at
baseline, using a comprehensive diagnostic approach and close moni-
toring of NIV, is paramount to guide NIV initiation and early detection
of failure and need for invasive MV in cancer patients.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jcrc.2015.04.121.
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